Chemoprevention is the use of medicines, either alone or in combination, to prevent malaria infection and its consequences. This publication provides standardized approaches for monitoring and evaluating the efficacy of medicines used for intermittent preventive treatment of malaria in pregnancy, pe...rennial malaria chemoprevention (formerly known as intermittent preventive treatment of malaria in infants), seasonal malaria chemoprevention and intermittent preventive treatment of malaria in school-aged children. It follows the recent release of new and updated WHO recommendations on these interventions.
more
On 15–16 December 2020, WHO and the Medicines for Malaria Venture co-convened a technical consultation to consider the preferred product characteristics (PPCs) for drugs used in malaria chemoprevention. The main goal of the technical consultation was to agree on the most important PPCs for drugs t...o protect populations from malaria (chemoprevention), while considering relevant measures of efficacy and the safety data needed to support WHO policy recommendations.
more
Effective malaria case management requires quick access to diagnostics and antimalarial treatments to reduce illness and death. Artemisinin-based combination therapy (ACT) has been essential to malaria treatment since 2001, as it combines artemisinin for rapid parasite reduction with a partner drug ...to ensure complete cure. However, resistance to antimalarial drugs, where parasites survive standard doses, threatens malaria control.
more
Case Management; Guide for Tutors
The webpage from Medicines for Malaria Venture (MMV) focuses on efforts to develop and provide child-friendly antimalarial treatments. It highlights the challenges of treating malaria in children, who are among the most vulnerable to the disease, and the need for safe, effective, and easy-to-adminis...ter formulations. MMV collaborates with global partners to ensure access to pediatric antimalarial medicines, such as dispersible tablets and rectal treatments, especially in low-resource settings. The page emphasizes the importance of innovation, accessibility, and partnerships in reducing childhood malaria mortality.
more
The MSF malaria guidelines provide practical, evidence-based recommendations for diagnosing, treating, and preventing malaria, especially in low-resource settings. They cover uncomplicated and severe cases, recommend rapid tests and artemisinin-based therapies, and include special guidance for vulne...rable groups like children and pregnant women.
more
Malaria in pregnancy is a significant health problem in malaria-endemic areas. It not only causes substantial childhood morbidity and mortality but also increases the risks of adverse events for pregnant women and their developing fetuses. Most of the burden in these areas is due to infection with P...lasmodium falciparum. Artemisinin-based combination therapy (ACT) has been recommended as first-line treatment for uncomplicated P. falciparum malaria in all populations, including pregnant women in their second and third trimesters, since 2006. However, for women in their first trimester of pregnancy, WHO recommended as first-line treatment a combination of quinine and clindamycin.
Based on a review of the evidence conducted in 2022, WHO now recommends artemether–lumefantrine, the ACT with the most human safety data available, as the preferred treatment for uncomplicated P. falciparum malaria in the first trimester of pregnancy. This document presents all relevant evidence on the effects and safety in early pregnancy of artemisinins and partner medicines used in ACTs from both studies in experimental animals and observational studies in humans.
more